The current clinical trials seek participants.
DECIDE: Comparing an investigational therapy for relapsing remitting MS with a leading treatment
DECIDE is a global clinical trial of daclizumab: a new investigational therapy that may help control specific parts of the immune system that often attack nerves in MS. Ask a staff member to see if you're eligible for this study.
This study will:
- Compare daclizumab with a leading treatment, AVONEX® (interferon beta-1a).
- Evaluate whether daclizumab or AVONEX is more effective at reducing the number of relapses.
During this study, all participants will receive (at no cost):
- Either daclizumab or AVONEX.
- Study-related care and monitoring throughout.
For more information contact:
Jennifer West, CRC
Clinical Research Coordinator
Little Rock Diagnostic Clinic, P.A.
10001 Lile Drive
Little Rock, AR 72205-6217
www.lrdc.com
Phone: (501) 223-4532
Fax: (501) 223-4565
Email: jwest@lrdc.com
This information is also available in a printable PDF.